Quantitative Epistasis Analysis and Pathway Inference from Genetic Interaction Data

Inferring regulatory and metabolic network models from quantitative genetic interaction data remains a major challenge in systems biology. Here, we present a novel quantitative model for interpreting epistasis within pathways responding to an external signal. The model provides the basis of an experimental method to determine the architecture of such pathways, and establishes a new set of rules to infer the order of genes within them. The method also allows the extraction of quantitative parameters enabling a new level of information to be added to genetic network models. It is applicable to any system where the impact of combinatorial loss-of-function mutations can be quantified with sufficient accuracy. We test the method by conducting a systematic analysis of a thoroughly characterized eukaryotic gene network, the galactose utilization pathway in Saccharomyces cerevisiae. For this purpose, we quantify the effects of single and double gene deletions on two phenotypic traits, fitness and reporter gene expression. We show that applying our method to fitness traits reveals the order of metabolic enzymes and the effects of accumulating metabolic intermediates. Conversely, the analysis of expression traits reveals the order of transcriptional regulatory genes, secondary regulatory signals and their relative strength. Strikingly, when the analyses of the two traits are combined, the method correctly infers ∼80% of the known relationships without any false positives

A duplicate column study of arsenic, cadmium and zinc treatment in an anaerobic bioreactor based on a system operated by Teck Cominco in Trail, British Columbia

The study’s objective was to identify and profile the treatment mechanisms within an anaerobic bioreactor (ABR) designed to remove high concentrations of arsenic, cadmium and zinc from contaminated drainage. The experiment used duplicate 15.6 L ABR columns, containing limestone and an organic substrate. The design and operation parameters were based on a larger field scale system operated by Nature Works Remediation for Teck Cominco in Trail, British Columbia. After an acclimatization period, the experiment was conducted for six months at various hydraulic loadings intended to evaluate optimal and stressed conditions, as well as, the ABR’s ability to re-establish optimal conditions. The study suggested that cadmium and zinc were removed as metal sulphides after 20 hours residence time. The behaviour of arsenic was independent of cadmium and zinc, and the majority was removed within 7 hours residence time. This was attributed to its adsorption to iron. Correlations of arsenic and iron concentrations throughout the organic substrate demonstrated that adsorption was inconsistent and unreliable as a treatment mechanism without the subsequent oxic conditions at the column’s headwater. Considerations for the field were identified for treatment, management of hydraulic loadings, and maintenance of an ABR.Non UBCUnreviewedOthe

Improving the reactivity of phenylacetylene macrocycles toward topochemical polymerization by side chains modification

The synthesis and self-assembly of two new phenylacetylene macrocycle (PAM) organogelators were performed. Polar 2-hydroxyethoxy side chains were incorporated in the inner part of the macrocycles to modify the assembly mode in the gel state. With this modification, it was possible to increase the reactivity of the macrocycles in the xerogel state to form polydiacetylenes (PDAs), leading to a significant enhancement of the polymerization yields. The organogels and the PDAs were characterized using Raman spectroscopy, X-ray diffraction (XRD) and scanning electron microscopy (SEM)

Climate refugia: joint inference from fossil records, species distribution models, and phylogeography

Climate refugia, locations where taxa survive periods of regionally adverse climate, are thoughtto be critical for maintaining biodiversity through the glacial–interglacial climate changes of theQuaternary. A critical research need is to better integrate and reconcile the three major lines ofevidence used to infer the existence of past refugia – fossil records, species distribution modelsand phylogeographic surveys – in order to characterize the complex spatiotemporal trajectoriesof species and populations in and out of refugia. Here we review the complementary strengths,limitations and new advances for these three approaches. We provide case studies to illustratetheir combined application, and point the way towards new opportunities for synthesizing thesedisparate lines of evidence. Case studies with European beech, Qinghai spruce and Douglas-firillustrate how the combination of these three approaches successfully resolves complex specieshistories not attainable from any one approach. Promising new statistical techniques cancapitalize on the strengths of each method and provide a robust quantitative reconstruction ofspecies history. Studying past refugia can help identify contemporary refugia and clarify theirconservation significance, in particular by elucidating the fine-scale processes and the particulargeographic locations that buffer species against rapidly changing climate

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19. In this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals in the USA, Denmark, Switzerland, and Poland were recruited. Patients were eligible if they had laboratory-confirmed SARS-CoV-2 infection and COVID-19 symptoms for up to 12 days. Using a web-based application, participants were randomly assigned (2:1:2:1), stratified by trial site pharmacy, to sotrovimab 500 mg, matching placebo for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or matching placebo for BRII-196 plus BRII-198, in addition to standard of care. Each study product was administered as a single dose given intravenously over 60 min. The concurrent placebo groups were pooled for analyses. The primary outcome was time to sustained clinical recovery, defined as discharge from the hospital to home and remaining at home for 14 consecutive days, up to day 90 after randomisation. Interim futility analyses were based on two seven-category ordinal outcome scales on day 5 that measured pulmonary status and extrapulmonary complications of COVID-19. The safety outcome was a composite of death, serious adverse events, incident organ failure, and serious coinfection up to day 90 after randomisation. Efficacy and safety outcomes were assessed in the modified intention-to-treat population, defined as all patients randomly assigned to treatment who started the study infusion. This study is registered with ClinicalTrials.gov, NCT04501978. Between Dec 16, 2020, and March 1, 2021, 546 patients were enrolled and randomly assigned to sotrovimab (n=184), BRII-196 plus BRII-198 (n=183), or placebo (n=179), of whom 536 received part or all of their assigned study drug (sotrovimab n=182, BRII-196 plus BRII-198 n=176, or placebo n=178; median age of 60 years [IQR 50–72], 228 [43%] patients were female and 308 [57%] were male). At this point, enrolment was halted on the basis of the interim futility analysis. At day 5, neither the sotrovimab group nor the BRII-196 plus BRII-198 group had significantly higher odds of more favourable outcomes than the placebo group on either the pulmonary scale (adjusted odds ratio sotrovimab 1·07 [95% CI 0·74–1·56]; BRII-196 plus BRII-198 0·98 [95% CI 0·67–1·43]) or the pulmonary-plus complications scale (sotrovimab 1·08 [0·74–1·58]; BRII-196 plus BRII-198 1·00 [0·68–1·46]). By day 90, sustained clinical recovery was seen in 151 (85%) patients in the placebo group compared with 160 (88%) in the sotrovimab group (adjusted rate ratio 1·12 [95% CI 0·91–1·37]) and 155 (88%) in the BRII-196 plus BRII-198 group (1·08 [0·88–1·32]). The composite safety outcome up to day 90 was met by 48 (27%) patients in the placebo group, 42 (23%) in the sotrovimab group, and 45 (26%) in the BRII-196 plus BRII-198 group. 13 (7%) patients in the placebo group, 14 (8%) in the sotrovimab group, and 15 (9%) in the BRII-196 plus BRII-198 group died up to day 90. Neither sotrovimab nor BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes among adults hospitalised with COVID-19. US National Institutes of Health and Operation Warp Spee